Glutamate antagonists and Parkinson's disease: A review of clinical data

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 477-480

  Montastruc, J L ^a   Rascol, O ^a   Senard, J M ^a  

^a INSERM   (France)

Author keywords

Dopamine; Glutamate; Synaptic transmission

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DEXTROMETHORPHAN; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; IFENPRODIL; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUISQUALIC ACID;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; DEXTROMETHORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PARKINSON DISEASE; PIPERIDINES; RECEPTORS, GLUTAMATE;

EID: 0031009330     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00035-8     Document Type: Article

References (34)

1. 1. Albin, R. L.; Young, A. B.; Penny, J. B., The functional anatomy of the basal ganglia: implications for the therapy of Parkinson's disease. Trends in Neuroscience, 12, 285-286 1989.
2. 2. Bem, J. L.; Peck, R., Dextromethorphan: an overview of safety issues. Drug Safety, 7, 190-199 1992.
3. 3H] ifenprodil binding sites in the mouse brain. Journal of Pharmacology and Experimental Therapeutics, 260, 896-901 1992.
4. 4. Bonucelli, U.; Del Dotto, P.; Piccini, P.; Benge, F.; Corsini, G. U.; Muratorio, A., Dextromethorphan on parkinsonism. Lancet, 340, 53 1992.
5. 5. Carter, C.; Benavides, J.; Legendre, P.; Vincent, J. D.; Noel, F.; Thuret, F.; Lloyd, K.; Arbilla, S.; Zivkivic, B.; Mackenzie, E.; Scatton, B.; Langer, S. Z., Ifenprodil and SL 82-0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. Journal of Pharmacology and Experimental Therapeutics, 247, 1222-1232 1988.
6. 6. Carter, C. J.; Lloyd, K. G.; Zivkovic, B.; Scatton, B., Ifenprodil and SL 82-0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. Journal of Pharmacology and Experimental Therapeutics, 253, 475-481 1990.
7. 3H] (+)-3-PPP to sigma binding sites in rat brain. Neuroscience Letters, 116, 190-193 1990.
8. 8. Danysz, W.; Gossel, M; Zajaczkowski, W.; Dill, D.; Quack, G., Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. Journal of Neural Transmission [Parkinson's Disease Section], 7, 155-166 1994.
9. 9. Domino, E. F.; Sheng, J., N-Methyl-N-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys. Journal of Pharmacology and Experimental Therapeutics, 264, 221-225 1993.
10. 10. Girault, J. A.; Halpain, S.; Greengard, P., Excitatory amino-acid antagonists and Parkinson's disease. Trends in Neuroscience, 13, 325-326 1990.
11. 11. Graham, D.; Darles, G.; Langer, S. E., The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studies. European Journal of Pharmacology [Molecular Pharmacology Section], 226, 373-376 1992.
12. 12. Greenamyre, J. T.; O'Brien, C. F., N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Archives of Neurology, 48, 977-981 1991.
13. 13. Happert, J. L.; Catel, P.; Pilardeau, P.; Loisel, J. C., Emploi du vadilex dans le traitement des insuffisants vasculaires cérébraux. Vie Medicin, 57, 2334-2336 1976.
14. 14. Jackisch, R.; Link, T.; Neufang, B.; Koch, R., Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine. No evidence for direct dopaminomimetic or antimuscarinic properties. Archives of International Pharmacodynamics, 320, 21-42 1992.
15. 15. Kaur, S.; Starr, M. S., Antiparkinsonian activity of dextromethorphan in the reserpine-treated mouse. European Journal of Pharmacology, 280, 159-166 1995.
16. 16. Klockgether, T.; Turski, L., Excitatory amino-acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends in Neuroscience, 12, 285-286 1989.
17. 17. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Annals of Neurology, 28, 539-546 1990.
18. 18. Lannes, B.; Micheletti, G.; Warter, J. M.; Zwiller, J., Chronic administration of NMDA antagonists induces a facilitation of striatal dopaminergic D2 transmission in rat: behavioural and biochemical study. CR Academy of Science Paris, serie III, 387-394 1992.
19. 19. Meldrum, B.; Gairthwaite, J., Excitatory amino-acid neurotoxicity and neurodegenerative disease. Trends in Pharmacological Science, 11, 379-382 1990.
20. 20. Monaghan, D. T.; Bridges, R. J.; Cotman, C. W., The excitatory amino-acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annual Review of Pharmacology and Toxicology, 29, 365-402 1989.
21. 21. Montastruc, J. L., Recent advances in the clinical pharmacology of Parkinson's disease. Therapie, 46, 293-303 1991.
22. 22. Montastruc, J. L.; Fabre, N.; Rascol, O.; Senard, J. M.; Blin, O., N-Methyl-D-aspartate (NMDA) antagonists and Parkinson's disease: a pilot study with dextromethorphan. Movement Disorders, 9, 242 1994.
23. 23. Montastruc, J. L.; Rascol, O.; Senard, J. M., Current status of dopamine agonists in Parkinson's disease management. Drugs, 46, 384-393 1993.
24. 24. Montastruc, J. L.; Rascol, O.; Senard, J. M., Neuroprotective mechanisms in Parkinson's disease. Lancet, 347, 196 1996.
25. 25. Montastruc, J. L.; Rascol, O.; Senard, J. M.; Rascol, A., A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 55, 630-631 1992.
26. 26. Otomo, E.; Atarashi, J.; Azaki, G.; Ito, E.; Omae, T.; Kuzuka, F.; Nukuda, T.; Ebi, O., Comparison of vinpocetine with ifenprodil tartrate and dihydroergotoxine mesylate treatment and results of long-term treatment with vinpocetine. Current Therapy and Research, 37, 811-821 1985.
27. 27. Radek, R. J.; Giardina, W. J., The neuroprotective effects of dextroprothorphan on guinea-pig derived hippocampal slices during hypoxia. Neuroscience Letters, 139, 191-193 1992.
28. 28. Reynolds, I. J.; Miller, R. J., Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Molecular Pharmacology, 36, 758-765 1989.
29. 29. Saenz, R.; Tanner, C. M.; Albers, G.; Kurth, G.; Tetrud, J., A preliminary study of dextromethorphan as adjunctive therapy in Parkinson's disease. Neurology, 43 (A115), 15 1993.
30. 30. Scatton, B., The NMDA receptor complex. Fundamental Clinical Pharmacology, 7, 389-400 1993.
31. 31. Scotti de Carolis, A.; Popoli, P.; Pezzola, A.; Sagratella, S., Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. Archives of International Pharmacodynamics, 310, 132-141 1991.
32. 31a. Starr, M. S.; Starr, B. S.; Kaur, S., Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neuroscience and Biobehavioral Reviews, 21 437-446 1997.
33. + neurotoxocity by N-methyl-D-aspartate antagonists. Nature, 349, 414-418 1991.
34. 33. Wong, E. H. F.; Kemp, J. A., Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Annual Review of Pharmacology and Toxicology, 31, 401-425 1991.